Detalles de la búsqueda
1.
A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark.
Acta Oncol
; 62(3): 290-297, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37010239
2.
The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer.
Future Oncol
; 15(22): 2561-2569, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31215242
3.
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.
Breast Cancer Res Treat
; 172(2): 391-400, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30099635
4.
Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial.
J Clin Oncol
; 42(17): 2038-2049, 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38498781
5.
Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.
Breast Cancer (Auckl)
; 17: 11782234231203292, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37810797
6.
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.
NPJ Breast Cancer
; 6: 7, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140564
7.
Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay.
Breast Cancer
; 27(2): 266-276, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31654283
Resultados
1 -
7
de 7
1
Próxima >
>>